Floatz logo

Docetaxel

Radiation Therapy

Peking University First HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Radiation Therapy cohort.

Asset / SponsorPhaseRating
Epirubicin
Peking University First Hospital
Phase 2CCC
Axitinib
Peking University First Hospital
Phase 2CCC
Elacestrant
Azienda Ospedaliero-Universitaria Careggi
Phase 2CCC
Toripalimab
Peking University First Hospital
Phase 2CCC
Cyclophosphamide
Peking University First Hospital
Phase 2CCC

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →